| 全人源抗TRAIL-R1／-R2单克隆抗体肿瘤治疗的研究进展 |
| |
| 引用本文： | 宗卫娇,芦凤亮,刘晔,金艾顺. 全人源抗TRAIL-R1／-R2单克隆抗体肿瘤治疗的研究进展[J]. 实用肿瘤学杂志, 2014, 0(4): 344-348 |
| |
| 作者姓名： | 宗卫娇 芦凤亮 刘晔 金艾顺 |
| |
| 作者单位： | 哈尔滨医科大学基础医学院免疫教研室,哈尔滨150081 |
| |
| 基金项目： | 国家自然科学基金面上项目（81171973）;高校博士学科点专项科研基金（20112307110002）;黑龙江省青年科学基金项目（QC2011C039） |
| |
| 摘 要： | 目前全人源TRAIL受体（TRAIL-Rs）的单克隆抗体（单抗）对肿瘤靶向治疗已进入临床Ⅰ～Ⅳ期研究。TRAIL-Rs单抗可分别与死亡受体TRAIL-R1和TRAIL-R2结合，形成死亡诱导信号复合体（DISC），诱导肿瘤细胞凋亡，成为抗肿瘤抗体药物研发的热点之一。全人源TRAIL-Rs单抗与放疗、化疗药物或其它制剂以及免疫治疗方法联合应用在肿瘤治疗中取得了显著的效果，为临床抗肿瘤治疗提供了新方案。
|
| 关 键 词： | TRAIL TRAIL受体 TRAIL-Rs单抗 肿瘤治疗 |
Development of full human monoclonal Ab to human TRAIL - Rs for tumor therapy |
| |
| ZONG Weijiao,LU Fengliang,LIU Ye,JIN Aishun. Development of full human monoclonal Ab to human TRAIL - Rs for tumor therapy[J]. Journal of Practical Oncology, 2014, 0(4): 344-348 |
| |
| Authors: | ZONG Weijiao LU Fengliang LIU Ye JIN Aishun |
| |
| Affiliation: | Department of Immunology, Basic Medical Science College, Harbin Medical University, Harbin 150081, China |
| |
| Abstract: | Monoclonal antibodies （mAbs） to human TRAIL receptors （ TRAIL - Rs ） have been developed in tumor targeted therapy and currently used in clinical Ⅰ～Ⅳtrials. MAbs can bind death - receptors（ TRAIL - R1 and TRAIL- R2）and then results in formation of the death inducing signaling complex（ DISC ）and apoptosis of tumor cells. TRAIL - Rs mAbs have become one of the research and development hotspots of anti - tumor drugs. These mAbs have achieved remarkable results in combination with radio - or ehemo - therapy drugs or oth- er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment. |
| |
| Keywords: | TRAIL TRAIL receptors Human mAb Tumor therapy |
| 本文献已被 维普 等数据库收录！ |
